5th March 2010
Tullett Prebon plc
Acquisition of
OTC Valuations Limited
Tullett Prebon plc announces that it has reached agreement to acquire OTC
Valuations Limited ("OTC Val"), a provider of independent derivative valuation
services based in Vancouver, British Columbia, Canada.
The initial consideration for the acquisition is US$0.6 million (approximately
£0.4 million) payable in cash, with deferred consideration up to a maximum of
US$1.4 million (approximately £0.9 million) payable in cash subject to
achievement of certain future revenue targets.
OTC Val is being sold by its management shareholders, Miroslav Vanous, Robert
Sangha and Paul Bergbusch and other shareholders, being : David Bergbusch, John
Bergbusch, John Stingl, Gurdeep Gill, Adela Vanous, George Vanous Jr, Rizwan
Gehlen, Martin Drobny, Vlasta Drobny, Curtis Pyke, Gerald Pyke, Waldon Bent,
Sean Y Hwang, Lena Lai and Killarney Securities Corporation.
The acquisition is expected to be completed on or about March 17, 2010.
ENDS
For further information please contact:
Investors and Analysts Press
Nigel Szembel, Head of Communications Charlotte Kirkham
Tullett Prebon plc M:Communications
44 (0)7802 362088 44 (0)207 920 2331
nszembel@tullettprebon.com kirkham@mcomgroup.com
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.